NCT02389244
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02389244
Title A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)
Acronym REGOBONE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNICANCER
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Hopital Jean Monjoz Besançon 25030 France Details
Institut Bergonie Bordeaux 33076 France Details
Centre Francois Baclesse Caen 14176 France Details
Centre Georges Francois Leclerc Dijon 21079 France Details
Centre Oscar Lambret Lille 59020 France Details
Centre Léon Berard Lyon 69373 France Details
Institut Paoli Calmettes Marseille 13273 France Details
La Timone University Hospital Marseille 13385 France Details
ICM Val d'Aurelle Montpellier 34298 France Details
Centre Antoine Lacassagne Nice 06189 France Details
Hôpital Cochin Paris 75014 France Details
Institut Curie Paris France Details
Centre Eugene Marquis Rennes 35042 France Details
Institut de cancerologie de l'ouest site Rene Gauducheau Saint-Herblain 44805 France Details
Institut de Cancérologie Lucien Neuwirth (ICLN) Saint-Priest-en-Jarez 42270 France Details
Institut Claudius Regaud Toulouse 31052 France Details
CHU Bretonneau Tours 37000 France Details
Institut de cancerologie de lorraine alexis Vautrin Vandœuvre-lès-Nancy 54519 France Details
Gustave Roussy Villejuif 94800 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field